Nerinetide is under clinical development by NoNO and currently in the Phase I, Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Nerinetide’s likelihood of approval (LoA) and phase transition for Acute Ischemic Stroke took place on 23 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Nerinetide Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Nerinetide overview

Nerinetide is under development for the treatment of acute ischemic stroke including strokes with endovascular intervention, procedurally-induced strokes, aneurysmal subarachnoid hemorrhage, traumatic brain injury and ischemic cerebral stroke, retinal ischemia, pain, epilepsy, Alzheimer’s disease and anxiety. The therapeutic candidate is administered through intravenous infusion. NA-1 (also known as Tat-NR2B9c) acts by targeting  PSD-95 a postsynaptic scaffolding protein.

NoNO overview

NoNO is a pharmaceutical company that provides research, development and commercialization of medicines for the treatment of neurological disorders. It develops therapeutic targets NA-1, lead therapeutic and a proprietary inhibitor of PSD-95 proteins. It also develops TRPM7 and inhibitors of Src-ND2 interactions. NoNO develops products for common health disorders with unmet needs, including stroke, traumatic brain injury, pain, and others. The company holds expertise in the development of a safe and effective treatment for acute neurological disorders, especially acute ischemic stroke, subarachnoid hemorrhage and procedurally induced strokes. NoNO is headquartered in Toronto, Ontario, Canada.

Quick View Nerinetide LOA Data

Report Segments
  • Innovator
Drug Name
  • Nerinetide
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Cardiovascular
  • Central Nervous System
  • Ophthalmology
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.